



2021 ANNUAL REPORT

Who are we

Our Institutional
Partners

Our Data Entry
Operators

HCC Registry

Research

Education &
Training
Nursing Webinars

Education &
Training
Data Entry
Operators

Publications

Financial Report

Connect with us

<https://hemecancer.org/>

WHO ARE WE

Hematology Cancer Consortium (HCC) is a multi center collaborative organization established to fulfil the long felt need of good quality, cooperative group data in hematological malignancies in India.

OUR GOALS

- Aggregate clinical data to support care outcomes of hematological malignancies
- Develop evidence based, locally relevant treatment protocols and guidelines
- Run investigator initiated prospective collaborative clinical trials addressing regionally relevant questions and evaluating cost effective treatment strategies
- Continuous education to improve awareness and enhance knowledge of therapeutic options for standardization of care in hematological cancers



OUR INSTITUTIONAL PARTNERS

We began with 12 leading Cancer Centers as our institutional partner and we currently have 20 partners.



Believers Church
MEDICAL COLLEGE HOSPITAL



OUR DATA ENTRY OPERATORS



SARANYA BHASKAR
MALABAR CANCER CENTRE



MOITREYEE KALITA
GAUHATI MEDICAL COLLEGE AND
HOSPITAL



MAYUR DINGANKAR
TATA MEMORIAL HOSPITAL



SINI ANTONY
AMALA INSTITUTE OF MEDICAL
SCIENCES



NIVEDITA SAWANT
TATA MEMORIAL HOSPITAL



NAYANAMOL K R
BELIEVERS CHURCH MEDICAL
COLLEGE & HOSPITAL



JAGSAHIB KAUR
ASIAN INSTITUTE OF MEDICAL
SCIENCES




NALLA KARUNASRI
NIZAM'S INSTITUTE OF MEDICAL
SCIENCES

HCC REGISTRY


One of the goals of Hematology Cancer Consortium is to aggregate clinical data to support care outcomes of hematological malignancies.

In the year 2021, twenty centers across the country recorded 1082 Acute Myeloid Leukemia patients' information. The center wise distribution has been summarized in the graph.




HCC REGISTRY

In the year 2021, eighteen centers across the country recorded 1046 Acute Lymphocytic Leukemia patients' information. The center wise distribution has been summarized in the graph.




In the year 2021, eighteen centers across the country recorded 944 Chronic Myeloid Leukemia patients' information. The center wise distribution has been summarized in the graph.




HCC REGISTRY

In the year 2021, seventeen centers across the country recorded 139 Acute Promyelocytic Leukemia patients' information. The center wise distribution has been summarized in the graph.



In the year 2021, sixteen centers across the country recorded 2557 Lymphoma patients' information. The center wise distribution has been summarized in the graph.



RESEARCH

Study Title: Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (HCC pRISM-S)

- Duration of study: 5 years
- Date of Study commencement: 1st July 2020
- No of Centres participating in this study: 17
- CTRI Registration No: CTRI/2020/07/026450

Update: Accrual complete, data analysis ongoing

Study Title: Evaluation of the safety and efficacy of generic low-dose Dasatinib for frontline therapy in chronic-phase chronic myeloid leukemia – A multi-center phase II single-arm study (GLaD Study)

- Duration of Study: 2 years
- Date of Study commencement: October 2020
- No of Centers participating in this study: 11
- CTRI Registration No: CTRI/2020/10/028317
- Update: Accrual is complete. Last patient last follow-up (12-month follow-up) is due by mid of August 2022.

Study Title: COVID-19 Hematological Cancers Registry of India (CHCRI Study)

- Study Design: Observational [Patient Registry]
- Observational Model: Case-Only
- Time Perspective: Prospective and Retrospect
- Actual Study Start Date: 1st November 2020
- Update: Accrual is ongoing. 1330 cases registered.

Study Title: Outcomes and prognostic factors in patients with Burkitt's Lymphoma: Real World Data (BL Study)

- Study design: Observational, retrospective cohort
- Time Perspective: All consecutive patients registered between January 2012 to December 2019
- No of Centers participating in this study: 11
- Update: 9 centers have received approval and have completed registry data entry.

RESEARCH

Study Title: Epidemiology and treatment outcomes of patients older than 55 years of age with Acute Myeloid Leukemia in India. (HCC Elderly AML)

- Study design: Observational, retrospective cohort
- Time Perspective: All consecutive patients registered between January 2018 to April 2021, based on current WHO criteria
- No of Centers participating in this study: 17
- Update: 8 centers have received IEC approval.

Study Title: Care of patients with Acute Myeloid Leukemia during COVID in India - HCC Leucoin Study

- Study Design: Observational, retrospective comparative analysis of data between two time periods
- Time Perspective: A] 1st January 2018 to 31st March 2020 (pre-COVID-19)
B] 1st April 2020 to 31st August 2021 (COVID-19 era)
- No of Centers participating in this study: 17
- Update: 10 centers have received IEC approval.

UPCOMING CLINICAL TRIAL

Study Title: Phase III open labeled randomized controlled study to evaluate the optimal dose of all-trans retinoic acid in the treatment of low and intermediate risk acute promyelocytic leukemia. (HCC-APL22 DOSA Study).

- Study design: Phase III open labeled Randomized Control Trial
- Sample size: 280 patients (140 patients in each arm)
- Study duration: 3 years
- Objective: To evaluate the net treatment benefit (event-free survival, documented infections, differentiation syndrome, hepatotoxicity and neuropathy in decreasing order) between the two study arms.
- Indication: Patient newly diagnosed with Acute Promyelocytic Leukemia and age more than 15 years at diagnosis.
- Update: Protocol writing is complete. Designed ICF's and CRF. Site evaluation criteria is ready. Synopsis along with NDA has been shared with the members.

EDUCATION & TRAINING

NURSING WEBINARS

HCC nurses group had initiated an education program to enhance knowledge. Webinars are held on the last Tuesday of every month.

Topic	Speaker
Recognition and management of early complication in allogeneic HSCT: Nursing Perspective	Ms. Mita Roychowdhury, Clinical Nurse Specialist, Bone Marrow Transplant Unit, TMC, Kolkata
Role of nurses in apheresis	Ms. Josephine Suganya AMC, Apheresis Nurse, Hemato- Oncology Nursing Department, CMC Vellore
Role of car t - cell therapy in hematological malignancies	Mrs. Abijah Princy B, Nurse Manager, Department of Hematology, CMC Vellore
How to write a research proposal	Dr. Venkatraman Radhakrishnan, Professor & In-charge Medical Oncology, Cancer Institute (W.I.A)
Clinical transfusion practices for nurses	Ms. Manisha U G, Staff Nurse, ACTREC, Tata Memorial Center, Navi Mumbai
Nursing management of side effects of chemotherapy	Mrs. Reena Nair, ANS, Tata Memorial Hospital, Mumbai
Transforming nursing practice: Nursing Research	Mrs. Sangeetha Samuel, Deputy Nursing Superintendent / Assistant Professor, Christian Medical College & Hospital, Ludhiana
Role of immunotherapy in cancer treatment	Mrs. Abijah Princy B, Nurse Manager, Hemato- Oncology Nursing Department, CMC Vellore
CVAD- PICC Insertion care & maintenance	Ms. Sheelpa N Raskar, Sr. Nurse Department of CVAD, Tata Memorial Hospital, Mumbai

EDUCATION & TRAINING

DATA ENTRY OPERATOR

HCC conducted training programs for our Data Entry Operators in collaboration with the BIRAC, CDMC & NCG teams.

BIRAC team conducted 12 training programs on various topics.

ICMR Guidelines	Clinical Trial Monitoring	Source Documents
Essential Documents	ICH GCP guideline E6 R2	Investigator responsibilities
Sponsor Responsibilities	Investigational Product Management	Root Cause Analysis (RCA) and Corrective and Preventive Actions (CAPA)
Safety Reporting in CTs	Audits	Audit and Inspection

DEOs also attended the “Clinical Research Methodology - CRM 2021” workshop organized by Tata Memorial Center.

We conducted a special workshop for DEO's on 6th & 7th August 2021

Basics about Hematologic cancers

Dr. Uday Kulkarni

Overview & explanation of terminologies used in software

- AML : Dr Smita Kayal
- ALL : Dr Prasanth Ganesan
- CML : Dr Hasmukh Jain
- APML : Dr Uday Kulkarni
- Lymphoma : Dr Anu Korula

Introduction to data collection, basic biostatistics and terminologies



Dr Jeyaseelan

Hands on experience on the software

Mr Omprakash

PUBLICATIONS

We are glad to announce that the manuscript submitted to the Blood Cancer Journal titled "Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India" by HCC has been published.



COVID-19 diagnosis time point		
66% patients - within 6 months of HM diagnosis		
30% patients were in remission	76% patients were receiving active anticancer therapy	
In the previous 4-weeks as a part of their treatment for HM	50% received steroids	15.2% received monoclonal antibodies

Limitation	Strength
The significant limitations of this study are referral bias, differential access to healthcare, heterogeneous treatment policies with the data source limited to tertiary referral centers	The strengths of the study include a large data set from one of the severely COVID-19 hit, low SDI regions.
The true denominator of cases from a given site was not known	This study comprises broad haematological malignancies including leukemia, lymphoma, and myeloma, with a relatively longer follow-up post-COVID-19.
Though treatment interruption or de-escalation was not prospectively captured in a fraction of patients, the study does indicate the need to keep the interruptions/de-escalations to a minimum to avoid the increased risk of mortality, specifically in those patients not in remission	As the study included patients from India up to March 20, 2021, most of the patients were unvaccinated, and therefore, the impact of vaccination in this population was not analysed

In conclusion, the study highlights the high mortality due to COVID-19 in patients with HM, especially AML and post HCT patients. More than one billion population in India is already vaccinated & it will be interesting to know the impact of the COVID-19 vaccine on the outcome of cancer patients in the future.

FINANCIAL REPORT

Balance sheet as at March 31, 2022

Hematology Cancer Consortium- Association			
CIN :- U85100MH2020NPL335745			
Balance Sheet as At March 31, 2022		In ₹ (Hundred Of Rupees)	
Particulars	Note No.	As at 31-Mar-2022	As at 31-Mar-2021
EQUITY AND LIABILITIES			
Sources of Funds			
(a) Corpus fund		-	-
(b) Reserves and Surplus	1	44,825.28	30,699.64
Current Liabilities			
(a) Trade Payables			
(b) Other Current Liabilities	2	3,940.83	77,631.85
Total		48,766.11	1,08,331.49
ASSETS			
Non-Current Assets			
(a) Fixed Assets	3	1,711.37	
(b) Other Non-Current Assets	4	1,222.91	322.91
Current Assets			
(a) Cash and Cash Equivalents	5	45,208.94	1,07,154.75
(b) Prepaid Expenditure		528.36	712.04
(c) Misc Expenditure		94.53	141.79
Total		48,766.11	1,08,331.49


Significant Accounting Policies & Notes to Accounts

As per our report attached.

For M. P. Chitale & Co.

Chartered Accountants

Firm Regn. No.101851W


Ashutosh Pednekar

Partner

M No.: 041037

Date: July 05, 2022

Place: Mumbai



For and On behalf of the Board

Hematology Cancer Consortium- Association


NIYATI SUTARIA JAMES

Director

DIN: 09428177

Date: July 05, 2022

Place: Mumbai


PALANI THYAGARAJAN

Director

DIN: 09428178

Date: July 05, 2022

Place: Mumbai



FINANCIAL REPORT

Statement of Income and Expenditure for the period ended March 31, 2022

Hematology Cancer Consortium- Association
CIN :- U85100MH2020NPL335745

Statement of Income and Expenditure for the period ended March 31, 2022

In ₹ (Hundred Of Rupees)

SR No	Particulars	Note No.	FOR THE YEAR ENDED ON 31-MAR-22	FOR THE PERIOD ENDED ON 31-MAR-21
I	Donations, Grants & Sponsorships	6	1,19,781.97	52,419.36
II	Other Income	7	2,366.23	1,254.85
III	TOTAL REVENUE (I + II)		1,22,148.20	53,674.21
IV	EXPENSES			
	Expenses on Objects of Section 8 Company	8	1,07,389.81	22,880.05
	Depreciation		379.53	-
	Amortization of preliminary expenses		47.26	94.52
	Administration Expenditure		205.96	-
	TOTAL EXPENSES		1,08,022.56	22,974.57
V	Surplus Before Tax		14,125.64	30,699.64
VI	Tax Expense		-	-
	Current Tax		-	-
	Deferred Tax		-	-
VII	Surplus for the Period(V-VI)		14,125.64	30,699.64

The Notes referred to above form an integral part of the Balance Sheet.

As per our report attached.

For M. P. Chitale & Co.

Chartered Accountants

Firm Regn. No.101851W

Ashutosh Pednekar
Partner

M No.: 041037

Date: July 05, 2022

Place: Mumbai



For and On behalf of the Board

Hematology Cancer Consortium- Association

NIYATI SUTARIA JAMES
Director

DIN: 09428177

Date: July 05, 2022

Place: Mumbai

PALANI THYAGARAJAN
Director

DIN: 09428178

Date: July 05, 2022

Place: Mumbai



FINANCIAL REPORT

Cash flow statement

Hematology Cancer Consortium- Association		
CIN :- U85100MH2020NPL335745		
Cash flow statement for the period ended March 31, 2022		
In ₹ (Hundred Of Rupees)		
Particulars	31-Mar-2022	31-Mar-2021
A. Cash flow from operating activities		
Surplus Before Tax	14,125.64	30,699.64
Adjustments for:		
Depreciation and Amortization Expenses	426.79	94.52
Operating cash flows before changes in assets/liabilities	14,552.43	30,794.16
Changes in assets/liabilities		
Increase/(decrease) in other current liabilities	-73,691.02	77,631.85
(Increase)/decrease in Other Non current Assets	-900.00	-322.91
(Increase)/decrease in short-term loans and advances	230.94	-853.83
Cash generated from operating activities	-59,807.64	1,07,349.27
Amortization Expenses	-47.26	-94.52
Net cash flows generated from operating activities (A)	-59,854.90	1,07,154.75
B. Cash flow from investing activities		
Purchase of fixed assets	-2,090.90	-
Net cash flow generated from investing activities (B)	-2,090.90	-
C. Cash flow from financing activities		
Issue of share capital	-	-
Net cash flow generated from financing activities (C)	-	-
Net increase in cash and cash equivalents (A+B+C)	-61,945.81	1,07,154.75
Cash and Cash Equivalents as at the beginning of the year	1,07,154.75	-
Cash and Cash Equivalents as at the end of the year	45,208.94	1,07,154.75

The Notes referred to above form an integral part of the Balance Sheet.

As per our report attached.

For M. P. Chitale & Co.
Chartered Accountants
Firm Regn. No.101851W

Ashutosh Pednekar
Partner

M No.: 041037

Date: July 05, 2022
Place: Mumbai



For and On behalf of the Board
Hematology Cancer Consortium- Association

NIYATI SUTARIA JAMES
Director

DIN: 09428177

Date: July 05, 2022
Place: Mumbai

PALANI THIYAGARAJAN
Director

DIN: 09428178

Date: July 05, 2022
Place: Mumbai



FINANCIAL REPORT

Fixed Assets

Hematology Cancer Consortium- Association											
CIN:- 085100MH2020NPL335745											
3 -FIXED ASSETS											
DESCRIPTION	RATE	GROSS BLOCK				DEPRECIATION/AMORTIZATION				NET BLOCK	
		AS ON 01.04.2021	ADDITIONS DURING THE YEAR	SALES/ADJ. DURING THE YEAR	AS ON 31.03.2022	PROVIDED UPTO 31.03.2021	DEDUCTION/ ADJUSTMENT	PROVIDED FOR THE YEAR	TOTAL UPTO 31.03.2022	AS ON 31.03.2022	AS ON 31.03.2021
Computer	31.67%	-	2,090.90	-	2,090.90	-	-	379.53	379.53	1,711.37	-
TOTAL (A)		-	2,090.90	-	2,090.90	-	-	379.53	379.53	1,711.37	-
PERVIOUS YEAR		-	-	-	-	-	-	-	-	-	-
TOTAL ASSETS		-	2,090.90	-	2,090.90	-	-	379.53	379.53	1,711.37	-



[Handwritten signature]



FINANCIAL REPORT

Schedules

Hematology Cancer Consortium- Association		
CTIN:- U85100MH2020NPL335745		

Schedule 1 : Reserves & Surplus

	31-Mar-2022	31-Mar-2021
Opening Balance	30,699.64	
Add: Surplus carried over from balance sheet	14,125.64	30,699.64
Total	44,825.28	30,699.64

Schedule 2 :Current liabilities & provisions

	31-Mar-2022	31-Mar-2021
Sundry Creditors	1,416.00	-
Payable to Director(s)	-	236.31
Audit Fee	300.00	250.00
Professional Fees	-	138.74
Grant Payable	2,224.83	77,006.80
Total	3,940.83	77,631.85

Schedule 4 :Other Non-Current Assets

	31-Mar-2022	31-Mar-2021
TDS Receivable	1,220.65	320.65
Others	2.26	2.26
Total	1,222.91	322.91

Schedule 5:Cash & Bank Balances

	31-Mar-2022	31-Mar-2021
Cash in hand		-
Bank Balances in Savings Account with HDFC Bank		
Account No. 50100347097089	37,611.10	27,706.28
Account No. 50100392097440	7,330.56	79,198.47
Fixed Deposits	250.00	250.00
Interest Accrued on Fixed Deposits	17.28	-
Total	45,208.94	1,07,154.75

Schedule 6:Donations, Grants & Sponsorships

	31-Mar-2022	31-Mar-2021
Donation	-	27,500.00
Grant	1,19,781.97	3,543.21
Sponsorship	-	21,376.15
Total	1,19,781.97	52,419.36

Schedule 7:Other Income

	31-Mar-2022	31-Mar-2021
Saving Bank Interest	2,348.95	1,254.85
FDR Interest	17.28	-
Total	2,366.23	1,254.85

Schedule 8:Expenses on Objects of Section 8 Company

	31-Mar-2022	31-Mar-2021
Research Activity	89,543.06	4,219.04
Professional Fees	11,958.19	17,174.45
Training Cost (Communication cost)	2,095.92	-
Insurance	1,074.68	526.96
Audit Fee	300.00	250.00
Other Expenditure	2,417.95	709.60
Total	1,07,389.81	22,880.05



[Handwritten signatures]



FINANCIAL REPORT

Notes forming part of the financial statements as at the year ended March 31st, 2022

Hematology Cancer Consortium-Association
NOTES FORMING PART OF THE FINANCIAL STATEMENTS AS AT THE YEAR
ENDED MARCH 31st, 2022

1. Corporate Information:

Hematology Cancer Consortium-Association (the Company) is a private company limited by guarantee registered under section 8 of the Companies Act, 2013. The Company was incorporated on January 09, 2020. Object of the company is to initiate a web based online data collection platform for hematological cancers, bio-banking of samples from cases with hematological cancers in each of the participating centers, analyzing the respective data and plan prospective collaborative studies in the relevant field, facilitating basic scientific research to understand the biology of the disorders, developing common treatment protocols and specific guidelines for management of hematological cancers, disseminating the knowledge and information to the physicians, patients, volunteers and other sections of the society as may be deemed fit, facilitating access to standard care treatment for patients diagnosed with hematological cancers and to do all the related or supportive or ancillary activities with respect to hematological cancers.

2. Significant Accounting Policies:

a. Basis of Accounting

The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and the relevant provisions of the Companies Act, 2013 ("the 2013 Act"). The financial statements have been prepared on accrual basis under the historical cost convention.

The Company is a Small and Medium size Company (SMC) as defined in the general instructions. In respect of Accounting Standards notified under the Companies Act, 2013. Accordingly, the Company has complied with the Accounting Standards as applicable to small and medium size Company.

b. Use of Estimates

The preparation of financial statements in conformity with Generally Accepted Accounting Principles require estimates and assumptions to be made that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and differences between actual results and estimates are recognized in the periods in which the results are known/materialize.



FINANCIAL REPORT

Notes forming part of the financial statements as at the year ended March 31st, 2022

cont..

c. **Revenue Recognition**

Donations received towards Hematology Cancer Consortium-Association are considered as income when received. Grants and Sponsorship are recognized as income based on the irrespective contractual terms. Revenue is recognized when it is earned and no significant uncertainty exists as to its realization or collection.

d. **Corpus Funds**

Receipts in the form of voluntary contribution made with a specific direction to be treated as corpus are recognized as Corpus Funds.

e. **Related party transactions.**

Description of Relationship	Names of related parties	1-April-2021 to 31-Mar-2022
Key Management Personnel (KMP)	Remuneration Bhavisha Sanadhya – CEO(w.e.f.8 th December 2021)	Rs 2,70,000 (PY Rs. Nil)

f. **In Income Tax**

Current tax, if any is the amount of tax payable on the taxable income for the year as determined in accordance with the applicable tax rates and provision of the Income Tax Act, 1961.

g. **Provisions, Contingent Liabilities & Contingent Assets**

A provision is recognized when the company has a present legal obligation as a result of past events and it is probable that an out flow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions (excluding employee benefits) are not discounted to present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

h. **Depreciation**

Depreciation on property, plant and equipment is provided on the straight-line method at the rates reflective of the estimated useful life of the assets estimated by the management.

i. The Company is registered under section 8 of the Companies Act, 2013. The Company is exempt from the payment of Income tax. No provision for taxation has been made in the accounts in view of the exemption eligible to the Company under Section 11 read with Section 2(15) of the Income tax Act 1961.



2






FINANCIAL REPORT

Notes forming part of the financial statements as at the year ended March 31st, 2022

cont..

- j. The Company has not granted any advance/loans or investments or provided guarantee or security or the like to any other person(s) or entities with an understanding, whether recorded in writing or otherwise, to further lend/invest/provide guarantee or security or the like to any other person on behalf of the company.
- k. The Company has not received any funds from any person(s) or entities with an understanding, whether recorded in writing or otherwise, that the company shall further lend or invest or provide guarantee or security or the like in any other person on behalf of and identified by such person(s)/entities.
- l. Previous year figures have been regrouped/reclassified wherever necessary, in order to make them comparable.

For M. P. Chitale & Co. Chartered Accountants FRN: 101851W  Ashutosh Pednekar Partner M No.:041037 Date : July 5, 2022 Place: MUMBAI	For and on behalf of the Board of Directors  NIYATI SUTARIA JAMES Director DIN: 09428177 Date : July 5, 2022 Place: MUMBAI  PALANI THYAGARAJAN Director DIN: 09428178 Date : July 5, 2022 Place: MUMBAI
--	--



CONNECT WITH US

HCC is deeply grateful to its individual & corporate supporters for their generosity.

You can join us on:



CONTACT US

EMAIL: ADMIN@HEMECANCER.ORG